Body Mass Index as a Risk Factor for Prostate Cancer and Benign Prostate Hypertrophy: a Comparative Study at Three Reference Hospitals in Cameroon

Sando Zacharie, Lemonge Norbert Nkapleweh, Mbassi Achille, Mekeme Junior Barthelemy, Fouogue Tsuala Jovanny, Fouelifack Ymele, Angwa Fo III F Fru


Introduction: Prostate cancer (PCa) is the second most commonly diagnosed cancer and the sixth most common cause of cancer-related mortality among men worldwide. Obesity increases the prevalence and mortality of multiple cancers. Consequently, the relationship between obesity and cancer is receiving more and more attention.

Objective: To evaluate the impact of body mass index (BMI) on prostate cancer detection and aggressiveness in Cameroonian population.

Methodology: This was a comparative cross-sectional study carried out at the hospitals in Cameroon. The study included Cameroonians who underwent prostate biopsies during a 9-year period, from 2008 to 2016. We analysed the BMI, age, prostate volume, and PSA of patients with prostate cancer in comparison with patients with benign prostate tissue who underwent prostate biopsies. Data entry was performed using CSpro 6.3.2, analysis was done using SPSS version 23.0.

Results: A total of 316 patients were included in our study, 158 PCa and 158 BPH. The patients had a mean age ± standard deviation of 67.8 ± 10.32 with a modal class of 61 and 70 years. In our study, the mean age ± SD of the PCa group (71.48 ± 8.96) was significantly greater than that of the BPH group (64.17 ± 10.31) (p<0.001).The PCa group had a mean BMI ± SD of 24.80 ± 4.07 while in the BPH group it was 24.49 ± 3.68, p = 0.472. Amongst the patients with high BMI, 71(52.2%) had prostate cancer while 65 (47.8%) had benign tissue. Amongst the patients with low BMI, 87(48.3%) had prostate cancer while 93 (51.4%) had benign tissue. The odds ratio was 1.168 with a 95% confidence interval of 0.748 to 1.823 (p>0.05). The median total PSA and the median PSA f/t ratio was significantly different in both groups (p<0.001 and p = 0.006). A Gleason score of 7 was the most frequent. Amongst those with a high BMI 77.5% (55) had a high Gleason score, which was significantly higher than the fraction in the low BMI group (60.9%) (53) (P = 0.026).

Conclusion: We therefore conclude that BMI is not an independent risk factor for the development of prostate cancer; rather, it is associated with High Gleason PCa.


BPH, BMI, Gleason Score, Prostate cancer

Full Text:



Torre LA, Bray F, Siegel RL et al. Global cancer statistics,

CA Cancer J Clin 2015; 65(2): 87-108.

Ferlay J, Soerjomataram I, Dikshit R et al. Cancer

incidence and mortality worldwide: Sources, methods

and major patterns in GLOBOCAN 2012. Int J Cancer

; 136(5): 359-86.

Center MM, Jemal A, Lortet-Tieulent J et al. International

variation in prostate cancer incidence and mortality

rates. Eur Urol 2012; 61(6): 1079-1092.

Angwafo FF, Yomi J, Mbakop A. Is cancer of the prostate

rare in tropical (black) Africa? Case series from The

Centre Hospitalier et Universitaire and the Hospital

General de Yaounde from 1986 to 1990. Bull Cancer

Radiotherapie 1994; 81(2): 155-159.

Enow Orock GE, Ndom P, Doh AS. Current cancer

incidence and trends in Yaounde, Cameroon. Oncol

Gastroenterol Hepatol Rep 2012; 1(1): 58-63.

Graham J, Baker M, Macbeth F et al. Diagnosis and

treatment of prostate cancer: summary of NICE

guidance. BMJ 2008; 336(7644): 610-612.

Isbarn H, Jeldres C, Budäus L et al. Effect of body mass

index on histopathologic parameters: results of large

European contemporary consecutive open radical

prostatectomy series. Urology 2009; 73(3): 615-619.

Swinburn BA, Sacks G, Hall KD et al. The global

obesity pandemic: shaped by global drivers and local

environments. Lancet Lond Engl 2011; 378(9793):


Kamadjeu RM, Edwards R, Atanga JS et al.

Anthropometry measures and prevalence of obesity

in the urban adult population of Cameroon: an update

from the Cameroon Burden of Diabetes Baseline

Survey. BMC Public Health 2006; 6: 228.

Allott EH, Masko EM, Freedland SJ. Obesity and prostate

cancer: weighing the evidence. Eur Urol 2013; 63(5):


Freedland SJ, Aronson WJ. Examining the relationship

between obesity and prostate cancer. Rev Urol 2004;

(2): 73-81.

Wooding AE, Rehman I. Obesity and prostate cancer:

Is there a link? E-SPEN J 2014; 9(3): 123-130.

WHO: Global Database on Body Mass Index. Cited

Nov 15. Available from:


Feng Z, Xi C, Jinxian P et al. Correlation between body

mass index (BMI) and the Gleason score of prostate

biopsies in Chinese population. Oncotarget 2016;

(39): 63338-63341.

Nwofor AME, Oranusi CK. Cancer of the prostate:

experience at Nnewi, Southeast, Nigeria. Niger J Clin

Pract 2004; 7(2): 65-68.

Fouda PJ, Moby Mpay EH, Mekeme M J et al. La symptomatologie

du bas appareil urinaire de l’homme à

l’hôpital central de Yaoundé. à propos de 329 cas.

Health Science and disease 2013; 14(3): 1-5.

Liang Y, Ketchum NS, Goodman PJ et al. Is there a role

for body mass index in the assessment of prostate

cancer risk on biopsy?. J Urol 2014; 192(4): 1094-1099.

Lee A, Chia SJ. Prostate cancer detection: The impact

of obesity on Asian men. Urol Oncol 2015; 33(6): 17-22.


  • There are currently no refbacks.

Copyright (c) 2018 Recent Advances in Pathology & Laboratory Medicine (ISSN: 2454-8642)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.